Orexo
23.30 SEK
-1.89 %
Less than 1K followers
ORX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Orexo
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 844.8 | 663.6 | 565.0 | 624.3 | 638.8 | 590.0 | 26.0 |
| growth-% | -21.4 % | -14.9 % | 10.5 % | 2.3 % | -7.6 % | -95.6 % | |
| EBITDA | 272.2 | 19.0 | -161.1 | -180.4 | -9.7 | 23.4 | 772.3 |
| EBIT | 231.2 | -19.9 | -214.1 | -183.9 | -109.5 | -140.3 | -352.7 |
| Profit before taxes | 227.9 | -38.3 | -222.5 | -170.4 | -140.3 | -190.6 | -403.0 |
| Net income | 219.1 | -84.4 | -223.5 | -177.6 | -128.3 | -203.0 | 639.3 |
| EPS | 6.33 | -2.44 | -6.51 | -5.17 | -3.73 | -5.89 | 18.46 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | 0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | 0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 32.2 % | 2.9 % | -28.5 % | -28.9 % | -1.5 % | 4.0 % | 2,970.4 % |
| EBIT-% | 27.4 % | -3.0 % | -37.9 % | -29.5 % | -17.1 % | -23.8 % | -1,356.5 % |
| ROE | 31.0 % | -15.1 % | -63.9 % | -91.6 % | -217.8 % | 160.7 % | 130.3 % |
| ROI | 14.6 % | -6.8 % | -17.5 % | -16.0 % | -16.3 % | -34.1 % | 49.1 % |